U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 1,146 results

Status:
US Approved Rx (2023)
First approved in 2023

Class (Stereo):
CHEMICAL (ABSOLUTE)



Durlobactam is a new member of the diazabicyclooctane class of beta-lactamase inhibitors with broad-spectrum activity against Ambler class A, C, and D serine beta-lactamases. Sulbactam is a first-generation beta-lactamase inhibitor with activity limi...
Status:
US Approved Rx (2023)
First approved in 2023

Class (Stereo):
CHEMICAL (ABSOLUTE)



Elacestrant (ER-306323 or RAD 1901 [6R)-6-(2-(N-(4-(2-(ethylamino)ethyl)benzyl)-N-ethylamino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol dihydrochloride]) is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). In ERpo...
Status:
US Approved Rx (2023)
First approved in 2023

Class (Stereo):
CHEMICAL (ABSOLUTE)



Leniolisib (JOENJA®) is an oral selective phosphoinositide 3-kinase-delta (PI3Kdelta) inhibitor being developed by Pharming Group NV in-licensed from Novartis for the treatment of immunodeficiency disorders. Leniolisib inhibits PI3K-delta by blocking...
Status:
US Approved Rx (2021)
First approved in 2021

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ponesimod is an experimental drug for the treatment of multiple sclerosis (MS) graft-versus-host disease and psoriasis. It acts on certain types of white blood cells (lymphocytes) which are involved in the autoimmune attack on myelin seen in multiple...
Status:
US Approved Rx (2020)
First approved in 2020

Class (Stereo):
CHEMICAL (ABSOLUTE)



Osilodrostat (INN, USAN) (developmental code name LCI-699) is an orally active, non-steroidal corticosteroid biosynthesis inhibitor which is under development by Novartis for the treatment of Cushing's syndrome and pituitary ACTH hypersecretion (a sp...
Status:
US Approved Rx (2020)
First approved in 2020

Class (Stereo):
CHEMICAL (RACEMIC)



Nifurtimox is a nitrofuran derivative used as a primary agent in the treatment of American trypanosomiasis (Chagas' disease) caused by Trypanosoma cruzi, especially in the acute, early stage of the disease. The efficacy of nifurtimox in the treatment...
Status:
US Approved Rx (2020)
First approved in 2020

Class (Stereo):
CHEMICAL (ABSOLUTE)



Lurbinectedin (PM-01183) - is a synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. Lurbinectedin covalently binds to residues lying in the minor groove of DNA, which may result in dela...
Status:
US Approved Rx (2020)
First approved in 2020

Class (Stereo):
CHEMICAL (ACHIRAL)



Opicapone (Ongentys®), a potent, oral, third-generation, long-acting, peripheral catechol-O-methyltransferase (COMT) inhibitor, is approved as the adjunctive treatment to levodopa (L-Dopa)/dopa-decarboxylase inhibitor (DDCI) therapy in adults with Pa...
Status:
US Approved Rx (2020)
First approved in 2020

Class (Stereo):
CHEMICAL (ACHIRAL)



Selumetinib (AZD6244 or ARRY-142886) is a potent, selective, and ATP-uncompetitive inhibitor of Ras-Raf-mitogen-activated protein kinase kinase (MEK1/2). This inhibition can prevent ERK activation, disrupt downstream signal transduction, and inhibit ...
Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (ABSOLUTE)


Bremelanotide (formerly PT-141) was developed for the treatment of female sexual dysfunction, hemorrhagic shock, and reperfusion injury. Bremelanotide, a synthetic peptide analog of α-melanocyte-stimulating hormone (α-MSH) is an agonist at melanocort...